THESES
Expression of the chemokines CXCL10 and CCL2 in serum and cerebrospinal fluid of patients with multiple sclerosis treated with intravenous methylprednisolone (Abstract)* * Expressão das quimiocinas CCL2 e CXCL10 no soro e líquido cefalorraquiano de pacientes com esclerose múltipla tratados com metilprednisolona intravenosa (Resumo). Dissertação de Mestrado, Faculdade de Ciências Médicas da Santa Casa de São Paulo (Área: Clínica Médica). Orientador: Charles Peter Tilbery. ** Address: Rua Cardoso de Almeida 634 / 93, 05013-000 São Paulo SP, Brasil. E-mail: drmarcosmoreira@uol.com.br . Dissertation. São Paulo, 2004
Marcos Moreira** * Expressão das quimiocinas CCL2 e CXCL10 no soro e líquido cefalorraquiano de pacientes com esclerose múltipla tratados com metilprednisolona intravenosa (Resumo). Dissertação de Mestrado, Faculdade de Ciências Médicas da Santa Casa de São Paulo (Área: Clínica Médica). Orientador: Charles Peter Tilbery. ** Address: Rua Cardoso de Almeida 634 / 93, 05013-000 São Paulo SP, Brasil. E-mail: drmarcosmoreira@uol.com.br
Studies of chemokines in cerebrospinal fluid (CSF) of patients with active multiple sclerosis have indicated that specific chemokines may develop an important role in the pathogenesis of the disease. Chemokines and its receptors have been associated with the migration of lymphocytes, monocytes, eosinophils, basophils and neutrophils under physiological and pathological conditions and have been considered important targets for investigation.
We have investigated the expression of two biologically important chemokines (CCL2 and CXCL10) in CSF and serum of 14 patients with relapsing multiple sclerosis (MS) and 14 controls with non-inflammatory CSF and 14 healthy individual's serum controls. We have also investigated the expression of these chemokines and the clinical alterations measured through Expanded Disability Status Scale (EDSS), Neurologic Rating Scale (NRS) and Ambulatory Index (AI) for MS before and after the treatment with intravenous methylprednisolone (IVMP) for five days.
In the admission, CCL2 concentrations were lower in MS patients than in controls; however, CXCL10 concentrations have demonstrated being higher in MS patients than in controls. The treatment has significantly changed the CCL2 and CXCL10 levels in CSF before and after the treatment. There was a statistically significant scores improvement of all the scales applied (EDSS, NRS and AI)soon after the end of the treatment.
Our results indicate that higher CXCL10 concentrations in the CSF and lower CCL2 concentrations are associated with relapses in multiple sclerosis.
Key words: multiple sclerosis, glucocorticoids, cerebrospinal fluid, chemokines, CXCL10; CCL2; methylprednisolone
Publication Dates
-
Publication in this collection
24 Aug 2004 -
Date of issue
Sept 2004
